This is a study of MK-5172 (grazoprevir [GZR]) (100 mg), MK-3682 (450 mg) and MK-8408 (ruzasvir) (60 mg) for 16 weeks with ribavirin (RBV) or 24 weeks without RBV in cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) genotype (GT) 1 or GT3-infected participants who have previously failed a direct-acting antiviral regimen (DAA). The combination regimen will be administered as two fixed-dose combination (FDC) tablets, referred to as MK-3682B, given once-daily.
Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
To read the entire clinical trial description, click here…
Cryoglobulinemia vasculitis (inflammation of blood vessels) is a disorder caused by the hepatitis C virus. The symptoms and health problems of cryoglobulinemia can be mild to moderate to severe and for some people cryoglobulinemia can be life-threatening. Treating cryoglobulinemia with direct-acting antiviral medications has been shown to improve the symptoms and complications of cryoglobulinemia and for some people successful HCV treatment can cure it.
This objective of this clinical trial is to treat and cure hepatitis C and measure the effect of curing hepatitis C on HCV-related cryoglobulinemia vasculitis.
France: Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
To view the entire clinical trial information, click here
This is an observation study to find out the ‘real world’ effectiveness (cure) of AbbVie’s Viekira Pak (with and without ribavirin) in genotype 1 and 4 patients. This includes treatment-naïve and treatment experienced patients. AbbVie’s drug combinations are approved by the Food and Drug Administration (FDA) to treat hepatitis C genotype 1 (cure rates = 95 to 100%) and genotype 4 (cure rates = 91 to 100%).
France: The Effectiveness of Paritaprevir/r – Ombitasvir, ± Dasabuvir, ± Ribavirin in France (OPALE)
To view the entire study description, click here
The study is recruiting HIV/HCV coinfected people with genotype 1 through 6 to determine the safety and effectiveness of the combination of ABT-493 plus ABT-530. The study is enrolling non-cirrhotic patients who will be treated for 8 weeks and compensated cirrhotic patients who will be treated for 12 weeks. In the completed Phase II studies the combination cured 97% to 100% of HCV genotype 1, 2 and 3 patients.
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)
To view the entire study description click here